Acadia Pharmaceuticals Stock News

Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) and Stoke Therapeutics Inc (NASDAQ: STOK ) will team up on the treatments in rare genetic neurodevelopmental diseases of the CNS. The recently discovered SYNGAP1 syndrome will be first, followed by Rett syndrome (MECP2) and an undisclosed target the biotechs say is of mutual interest. “Combining Stoke’s capabilities with Acadia’s extensive expertise in … Full story available on Benzinga.com

The stock of Acadia Pharmaceuticals (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, has seen a rise of 26% over the last month. ACAD stock rose from levels of around $19 in

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Guggenheim cut shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a buy rating to a neutral rating in a research note issued to investors on Tuesday morning, Analyst Price Targets reports. They currently have $28.00 price objective on the biopharmaceutical companys stock. A number of other equities research analysts also recently issued reports on the stock. The []

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Equities research analysts at Jefferies Financial Group lifted their FY2023 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Monday, December 20th. Jefferies Financial Group analyst C. Howerton now expects that the biopharmaceutical company will earn ($0.80) per share for the []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective hoisted by investment analysts at Canaccord Genuity from $26.00 to $30.00 in a report issued on Wednesday, Price Targets.com reports. The firm currently has a hold rating on the biopharmaceutical companys stock. Canaccord Genuitys price target indicates a potential upside of 23.46% from the stocks current price. ACAD []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective raised by investment analysts at JMP Securities from $39.00 to $42.00 in a note issued to investors on Tuesday, Price Targets.com reports. The firm presently has a market outperform rating on the biopharmaceutical companys stock. JMP Securities price target points to a potential upside of 75.59% from the []

The biotech saw a rebound after a down day on Tuesday.

The biotech saw a rebound after a down day on Tuesday.

The biotech saw a rebound after a down day on Tuesday.

Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. The stock is currently down 49.3% year-to-date, down 51.0% over the past 12 months, and down 5.2% over the past five years. Today, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $27.19 and as low as $20.84 this week.Shares closed 62.5% below its 52-week high and 36.8% above its 52-week low.Trading volume this week was 45.3% higher than the 10-day average and 105.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -274.5% The company's stock price performance over the past 12 months lags the peer average by -293.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective hoisted by Royal Bank of Canada from $32.00 to $34.00 in a research note released on Tuesday, Price Targets.com reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical companys stock. A number of other research analysts also recently issued reports on ACAD. Oppenheimer boosted [] The post ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Increased to $34.00 by Analysts at Royal Bank of Canada appeared first on ETF Daily News .